Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height.

Chiocca E, Dati E, Baroncelli GI, Mora S, Parrini D, Erba P, Bertelloni S

Neuroendocrinology29 Jan 2009Cited by 26 (Europe PMC)

PMID19176945DOI10.1159/000197862PepBankPUB-19176945

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
Previous triptorelin treatment was linked to higher total fat mass than in healthy adolescent controls.
In plain wordsPrevious triptorelin treatment was linked to higher total fat mass than in healthy adolescent controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseTotal fat mass
Study
n = 43
Comparator
Healthy adolescents with normal puberty
Outcome group
Body weight · Metabolic and weight
Studied dose
3.75 mg/28 daysAs given in this study (human).
Measurements
Total fat mass
16,144 g
Patients previously treated with triptorelin depot; SD 8,065
Total fat mass
10712.1 g
Healthy adolescent controls; SD 4,120.4
Source sentences
Summary
Total fat mass (TFM) was significantly increased (16,144 +/- 8,065 g; controls 10,712.1 +/- 4,120.4 g, p < 0.02); glucose homeostasis and lipid profile corresponded to reference ranges.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years.
Summary · context
23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls.
Report a problemFND-1917694505
02HumanObservational studyEfficacy outcome
Adolescents previously treated with triptorelin reached near adult height of -0.5 +/- 1.1 SDS.
In plain wordsAdolescents previously treated with triptorelin reached near adult height of -0.5 +/- 1.1 SDS.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableNear adult height
Study
n = 20
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg/28 daysAs given in this study (human).
Measurements
Near adult height SDS
−0.5 SDS
Patients previously treated with triptorelin depot; SD 1.1
Source sentences
Summary
Patients reached their near adult height (-0.5 +/- 1.1 standard deviation score (SDS)); the girls were menstruating and the majority (15/17) had regular cycles, the boys showed normal testicular function.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years.
Summary · context
23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls.
Report a problemFND-1917694501
03HumanObservational studyEfficacy outcome
In adolescents treated with triptorelin, BMI SDS did not change significantly from treatment initiation to near adult height.
In plain wordsIn adolescents treated with triptorelin, BMI SDS did not change significantly from treatment initiation to near adult height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBMI SDS
Study
n = 20
Outcome group
Body weight · Metabolic and weight
Studied dose
3.75 mg/28 daysAs given in this study (human).
Measurements
BMI SDS
0.4 SDS
Start of GnRH analogue therapy; SD 1.0
BMI SDS
0.2 SDS
Near adult height; SD 1.0
Source sentences
Summary
BMI was unchanged from the start of GnRH analogue therapy (0.4 +/- 1.0 SDS) to near adult height (0.2 +/- 1.0 SDS, p = NS vs. 0).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years.
Summary · context
23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls.
Report a problemFND-1917694504
04HumanObservational studyEfficacy outcome
Adolescents previously treated with triptorelin had glucose homeostasis within reference ranges.
In plain wordsAdolescents previously treated with triptorelin had glucose homeostasis within reference ranges.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableGlucose homeostasis
Study
n = 20
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.75 mg/28 daysAs given in this study (human).
Source sentences
Summary
Total fat mass (TFM) was significantly increased (16,144 +/- 8,065 g; controls 10,712.1 +/- 4,120.4 g, p < 0.02); glucose homeostasis and lipid profile corresponded to reference ranges.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years.
Summary · context
23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls.
Report a problemFND-1917694506
05HumanObservational studyEfficacy outcome
Adolescents previously treated with triptorelin had lipid profiles within reference ranges.
In plain wordsAdolescents previously treated with triptorelin had lipid profiles within reference ranges.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableLipid profile
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.75 mg/28 daysAs given in this study (human).
Source sentences
Summary
Total fat mass (TFM) was significantly increased (16,144 +/- 8,065 g; controls 10,712.1 +/- 4,120.4 g, p < 0.02); glucose homeostasis and lipid profile corresponded to reference ranges.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years.
Summary · context
23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls.
Report a problemFND-1917694507
06HumanObservational studyEfficacy outcome
All girls previously treated with triptorelin were menstruating, and 15/17 had regular cycles.
In plain wordsAll girls previously treated with triptorelin were menstruating, and 15/17 had regular cycles.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableMenstruation and cycle regularity
Study
n = 17
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg/28 daysAs given in this study (human).
Measurements
Girls with regular cycles
15 of 17 girls
Girls previously treated with triptorelin depot
Source sentences
Summary
Patients reached their near adult height (-0.5 +/- 1.1 standard deviation score (SDS)); the girls were menstruating and the majority (15/17) had regular cycles, the boys showed normal testicular function.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years.
Summary · context
23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls.
Report a problemFND-1917694502
07HumanObservational studyEfficacy outcome
Boys previously treated with triptorelin showed normal testicular function at near adult height.
In plain wordsBoys previously treated with triptorelin showed normal testicular function at near adult height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTesticular function
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg/28 daysAs given in this study (human).
Source sentences
Summary
Patients reached their near adult height (-0.5 +/- 1.1 standard deviation score (SDS)); the girls were menstruating and the majority (15/17) had regular cycles, the boys showed normal testicular function.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years.
Summary · context
23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls.
Report a problemFND-1917694503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.